Wall Street Journal Pro Venture Capital: Back Bay’s Jonathan Gertler Comments on Biotech IPO Market

Back Bay Life Science Advisors Founder and CEO, Jonathan Gertler, recently spoke with the Wall Street Journal reporter, Brian Gormley, about the biotech IPO market.In “Biotech Boosts Hopes for Long-Suffering IPO Market: Strong finish for 2017 could hinge on improved outlook for drugmakers,” Gormley wrote that “another dismal year of initial public offerings may be unfolding for technology startups, but investors see one bright spot on the horizon: biotech companies.”Dr. Gertler noted that in biotech’s early days, the window for companies to go public could be erratic. Now that the industry has matured, its IPO market is less likely to fizzle. 

A QUOTE FROM THE ARTICLE:

“It’s not just a speculative industry anymore,” Dr. Gertler said “The IPO market for biotechs should be reasonably dependable unless risk capital retreats completely.”

Wall Street Journal Pro Venture Capital subscribers can read the full article here.